Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study.
While immune checkpoint inhibitors (ICIs) are increasingly reshaping the therapeutic landscape of non-small-cell lung cancer (NSCLC), only a limited proportion of patients achieve a relevant and long-lasting benefit with these treatments, calling for the identification of clinical and, ideally modifiable,...
🗓️ 2024-10-22
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreBody composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study.